Immatics N.V. (NASDAQ:IMTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Immatics N.V. (NASDAQ:IMTX) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $16.00.

Several equities analysts have issued reports on IMTX shares. Guggenheim boosted their price target on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research report on Wednesday, October 8th. Mizuho set a $19.00 price target on shares of Immatics in a research report on Wednesday, October 29th. Finally, Zacks Research upgraded Immatics from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th.

Immatics Price Performance

Shares of NASDAQ:IMTX opened at $10.32 on Wednesday. Immatics has a 1 year low of $3.30 and a 1 year high of $11.25. The business’s 50-day moving average is $8.97 and its 200-day moving average is $6.85. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -10.12 and a beta of 1.24.

Hedge Funds Weigh In On Immatics

A number of hedge funds and other institutional investors have recently made changes to their positions in IMTX. Vontobel Holding Ltd. bought a new stake in shares of Immatics in the 2nd quarter worth approximately $59,000. Trexquant Investment LP purchased a new stake in Immatics in the first quarter worth $783,000. Fox Run Management L.L.C. bought a new stake in shares of Immatics in the second quarter valued at $136,000. Pale Fire Capital SE lifted its position in shares of Immatics by 8.9% during the 1st quarter. Pale Fire Capital SE now owns 34,270 shares of the company’s stock valued at $155,000 after buying an additional 2,808 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its stake in shares of Immatics by 38.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company’s stock worth $66,194,000 after acquiring an additional 4,072,226 shares during the period. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.